MACROGENICS, INC. Cash and Restricted Cash
MACROGENICS, INC. (MGNX) had Cash and Restricted Cash of $113.91 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $113.91M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $66.52M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $57.22M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $80.13M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $113.91M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $66.52M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $57.22M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $80.13M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $130.69M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $145.57M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $182.84M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $179.63M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $83.93M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $80.36M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $100.96M 10-K · filed 2026-03-09 |
| 2023-09-30 | $89.90M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $108.76M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $224.26M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $108.88M 10-K · filed 2026-03-09 |
| 2022-09-30 | $83.99M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $21.47M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $47.33M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $123.47M 10-K · filed 2025-03-20 |
| 2021-09-30 | $190.53M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $188.97M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $218.50M 10-Q · filed 2022-05-03 |
| 2020-12-31 | $181.13M 10-K · filed 2024-03-07 |
| 2020-09-30 | $201.64M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $196.53M 10-Q · filed 2021-07-29 |
| 2020-03-31 | $93.06M 10-Q · filed 2021-04-29 |
| 2019-12-31 | $126.47M 10-K · filed 2023-03-15 |
| 2019-09-30 | $156.59M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $180.32M 10-Q · filed 2020-07-31 |
| 2019-03-31 | $238.64M 10-Q · filed 2020-05-05 |
| 2018-12-31 | $220.13M 10-K · filed 2022-02-24 |
| 2018-09-30 | $201.81M 10-Q · filed 2019-11-06 |
| 2017-12-31 | $211.73M 10-K · filed 2021-02-25 |
| 2016-12-31 | $84.10M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |